PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 78 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $237,511 | -63.3% | 21,770 | -71.7% | 0.00% | -66.7% |
Q3 2022 | $648,000 | +50.0% | 76,862 | +40.6% | 0.00% | +50.0% |
Q2 2022 | $432,000 | +32.1% | 54,676 | +295.9% | 0.00% | +100.0% |
Q1 2022 | $327,000 | -84.2% | 13,810 | -77.2% | 0.00% | -80.0% |
Q4 2021 | $2,069,000 | +506.7% | 60,490 | +258.1% | 0.01% | +66.7% |
Q4 2020 | $341,000 | -90.0% | 16,893 | -85.7% | 0.00% | -94.5% |
Q2 2020 | $3,414,000 | +1203.1% | 118,120 | +218.5% | 0.06% | +685.7% |
Q1 2020 | $262,000 | -60.1% | 37,083 | -60.2% | 0.01% | +75.0% |
Q4 2019 | $656,000 | -35.0% | 93,103 | +10.8% | 0.00% | -55.6% |
Q3 2019 | $1,009,000 | -18.6% | 84,034 | -17.9% | 0.01% | -25.0% |
Q2 2019 | $1,239,000 | +120.1% | 102,337 | +128.5% | 0.01% | +100.0% |
Q1 2019 | $563,000 | +223.6% | 44,777 | +73.5% | 0.01% | +200.0% |
Q4 2018 | $174,000 | -53.2% | 25,804 | -28.5% | 0.00% | -50.0% |
Q3 2018 | $372,000 | +14.1% | 36,110 | -25.5% | 0.00% | 0.0% |
Q2 2018 | $326,000 | +129.6% | 48,467 | +193.2% | 0.00% | +100.0% |
Q1 2018 | $142,000 | – | 16,531 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $67,646,434 | 21.00% |
COWEN AND COMPANY, LLC | 1,657,551 | $45,781,558 | 3.80% |
Kynam Capital Management, LP | 975,298 | $26,937,731 | 3.70% |
BVF INC/IL | 3,775,900 | $104,290,358 | 2.91% |
RTW INVESTMENTS, LP | 5,415,514 | $149,576,497 | 2.85% |
Cormorant Asset Management, LP | 1,500,000 | $41,430,000 | 2.32% |
Ghost Tree Capital, LLC | 225,000 | $6,214,500 | 2.05% |
683 Capital Management, LLC | 814,000 | $22,482,680 | 1.62% |
Perceptive Advisors | 1,469,761 | $40,594,799 | 1.18% |
Artia Global Partners LP | 112,340 | $3,102,831 | 1.07% |